The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

PARP inhibitors are considered promising anti-cancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Velipari...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Oncol
Autores principales: Arun, Banu, Akar, Ugur, Gutierrez-Barrera, Angelica M., Hortobagyi, Gabriel N., Ozpolat, Bulent
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6904111/
https://ncbi.nlm.nih.gov/pubmed/25975349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2015.3003
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares